R Squared’s Vigil Neuroscience VIGL Stock Holding History

R Squared’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-910	Closed	-$1.55K	–	1484
2024 Q4	$1.55K	Buy	+910	New	+$2.69K	﹤0.01%	1486

Other funds holding VIGL

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

R Squared's VIGL Position: Q1 2025 in Review

R Squared sold out of Vigil Neuroscience (VIGL) in Q1 2025, closing a stake of 910 shares — an estimated $1.55K sold.

R Squared first reported a position in VIGL in Q4 2024 and held it in 1 quarter. The position peaked at $1.55K in Q4 2024. 50 funds tracked by Wall St. Rank hold VIGL as of Q1 2025.

R Squared reported no remaining Vigil Neuroscience position as of Q1 2025 after selling out during the quarter.
R Squared sold 910 Vigil Neuroscience shares in Q1 2025, an estimated $1.55K.
R Squared first reported a position in Vigil Neuroscience in Q4 2024 and held it in 1 quarter.
R Squared's Vigil Neuroscience position peaked at $1.55K in Q4 2024.
50 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.